C erebrovascular lesions, including white matter hyperintensities (WMH) and lacunar infarcts (LI), are common findings on brain magnetic resonance imaging (MRI) in older persons.
Previously, in a small randomized controlled trial in Alzheimer disease patients with cerebrovascular lesions on MRI, we found the treatment of multiple CVRFs diminished WMH progression, although without clinically detectable effects. 14 In this study, we aim to assess the effect of a nurse-led intervention targeting multiple CVRFs in community-dwelling older people without cognitive impairment but at increased risk of cerebrovascular lesion incidence and progression because of hypertension. Figure 1 provides a brief overview of the study. The preDIVA trial (Prevention of Dementia by Intensive Vascular Care) has been described in detail previously. 15 In brief, preDIVA was an open-label, cluster-randomized controlled trial in 3526 community-dwelling individuals aged 70 to 78 years, recruited through participating general practices in the Netherlands. General practices were randomly assigned via a computer-generated randomization sequence to either a 6-year intervention, comprising 4-monthly visits to a practice-nurse who addressed CVRFs using tailored lifestyle advice and medical interventions in consultation with the general practitioner, or a control condition comprising usual care ( Figure 1 ). Main outcomes were all-cause dementia and disability after 6 years of follow-up. Recruitment was from June 7, 2006 , until March 12, 2009 . Baseline data for demographic characteristics, cardiovascular and family history, medication use, and self-reported diet and smoking habits were collected and cross-checked with the participants' electronic health records. Cognitive function was assessed with the mini-mental state examination and visual association test. Anthropometrics and BP were measured according to a standard protocol, and blood samples were obtained for lipid spectrum and blood glucose measurements. Genomic DNA was stored and used for apolipoprotein-E genotyping. Measurements were repeated during 2 years of follow-up assessments by the practice-nurse at the general practitioner. The final follow-up assessment was conducted by independent investigators, blinded to treatment allocation. A consecutive subset of hypertensive intervention and control participants was invited at the 2-year assessment to undergo MRI. The only inclusion criterion was a systolic BP≥140 mm Hg at baseline (76% of participants, Figure 1) ; exclusion criteria were contraindications for MRI, dementia, or medical conditions likely to hinder successful 3-year follow-up (eg, terminal illness and advanced chronic obstructive pulmonary disease) at the time of MRI. Participants were invited until the sample size goal of ≈100 participants in each treatment arm was achieved. The first wave of MRI took place after the preDIVA 2-year assessment (scan 1), from June 17, 2011 , until July 20, 2012 (Figure 1 ). The second MRI wave (scan 2) was conducted around the time of final preDIVA assessment, from May 28, 2014 , to May 29, 2015. Sample size calculation for this MRI substudy was based on WMH progression in a previous observational study with participants in a comparable age range. 16 With α at 0.05, we had 80% power to detect an effect of 50% less WMH progression when including 64 subjects in each treatment arm. To account for unknown attrition and the possibility of less progression than expected, we aimed to include 100 participants in both treatment arms.
Methods

Participants and Intervention
PreDIVA was approved by the medical ethics committee of the Academic Medical Center, Amsterdam, the Netherlands. All participants gave written informed consent before their baseline visit. MRI substudy participants gave additional written informed consent before MRI. The preDIVA trial is registered with ISRCTN, number ISRCTN29711771. The MRI substudy was not registered separately. in-plane resolution) were collected. Because of hardware replacement, scan 2 was performed on a 3-Tesla Philips Ingenia scanner with a SENSE-16-channel head coil, obtaining the same sequences. To ensure that the hardware replacement would not unduly influence the longitudinal analyses, a purposive sample of 9 participants with WMH load varying from minimal to severe was scanned on both scanners with a median interval of 6.0 months (interquartile range, 5.6-6.9). Scanning parameters were identical. WMH volumes obtained showed excellent agreement between scanners (2-way mixed intraclass correlation coefficient 0.99, P<0.001; Figure I in the online-only Data Supplement).
MRI Acquisition
Assessment of Cerebrovascular Lesions and Brain Volumetrics
All assessments were performed blinded to treatment allocation. WMH were automatically segmented from fluid-attenuated inversion recovery scans using a k-nearest neighbor algorithm with tissuetype priors, described and validated previously. 17 Total brain volume (TBV) was calculated by adding gray and white matter volumes. LIs were identified by a trained rater on fluid-attenuated inversion recovery scans as round or ovoid, subcortical, fluid-filled (similar signal 
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as cerebral spinal fluid) cavities, between 3 and 15 mm in diameter, 1 regardless of whether these could be linked to any clinical symptoms. LIs identified on baseline scans were retraced on follow-up scans and vice versa. Participants were then categorized into increase or no increase in LI. T1 scans were bias field corrected, 18 and subsequently segmented using Statistical Parametric Mapping 12 19 to obtain gray and white matter volumes.
Statistical Analyses
The primary outcome was WMH progression, and the secondary outcome was occurrence of new LI. We used Fisher exact tests, Student's t tests, and Mann-Whitney U tests to compare baseline characteristics of participants recruited to the MRI substudy to those not recruited and of MRI participants in the final analyses to those not included because of the absence of follow-up MRI measurements. We used linear regression to analyze WMH volume change in milliliter per year predicted by randomization group. Model 1 adjusted for WMH volume at scan 1. As TBV may influence WMH volume, model 2 additionally adjusted for TBV at scan 1 and TBV change between scans (TBV scan 2/TBV scan 1). To account for baseline cardiovascular risk, model 3 additionally adjusted for age at scan 1, baseline diastolic and systolic BP, BMI, smoking, diabetes mellitus, serum cholesterol, history of cardiovascular disease (CVD), and history of stroke (including transcient ischemic attack [TIA]). Analyses were based on the intention-to-treat population. We assessed the occurrence of new LI using logistic regression adjusted for number of LI at scan 1 because existing LI are the greatest risk factor for new LI. Given the small number of incident LI, we did not analyze LI increase in further models to avoid spurious results. Sensitivity analyses for annual WMH increase comprised (1) exclusion of participants with stroke or LI at baseline or during follow-up because scarring or tissue loss caused by such lesions may unduly affect WMH volume, (2) use of annual change in WMH load (WMH volume/TBV) as outcome, as alternative adjustment for TBV, and (3) calculating the interaction between the intervention effect and the baseline WMH volume and assessing the intervention effect in each quartile of baseline WMH volume because the intervention effect may only be apparent in participants with high risk of WMH progression for which baseline WMH volume is the strongest risk factor. 20 For the analysis in quartiles, only models 1 and 2 were assessed because of the small numbers in each WMH volume group. Subgroup analyses were performed analogous to the preDIVA study according to treatment per protocol (intervention: mean ≥2 vascular care visits/year, control: mean <2 crossover vascular care visits/ year), sex, age dichotomized at the median, CVD/TIA/stroke history, apolipoprotein-E genotype (apolipoprotein-E 4 positivity is associated with WMH), 21 hypertension severity, antihypertensive use, hypertension control (systolic BP<150 mm Hg), cholesterol-lowering drug use, and treated/untreated cholesterol-lowering drug indication. The intervention effect on factors related to WMH progression (including BP, antihypertensive and cholesterol-lowering medication use, serum cholesterol, BMI, smoking, diabetes mellitus, CVD, stroke, mini-mental state examination score, and brain volume) was assessed using linear regression: for continuous measures with the mean value during the study as outcome, adjusted for baseline; for dichotomous variables, with new occurrence during the study, adjusted for baseline presence. Finally, we used linear regression to assess how these factors, at baseline and during the study adjusted for baseline, affected annual WMH volume change adjusted for baseline WMH. Potential J-or U-shaped relations 22 were explored by fitting quadratic curves and comparing regression coefficients within tertiles of continuous predictors.
Results
We included 96 intervention and 99 control participants ( Figure 1 ). Three had a baseline systolic BP<140 mm Hg but were left in the study. Compared with other preDIVA participants with a baseline systolic BP≥140 mm Hg, participants in the MRI substudy were younger, less likely to use antihypertensive drugs, less often smokers, had a lower BMI, higher serum cholesterol, less diabetes mellitus, and were less adherent to the intervention (Table I in the online-only Data Supplement). Of the 195 participants who underwent MRI, 135 (69%) attended the follow-up scan, on average 34 (SD=1.2) months later. Figure 1 lists reasons for nonparticipation: most frequent were medical conditions and the decision to discontinue participation in the preDIVA trial. WMH volumes were unavailable for 9 participants for technical reasons, leaving 126 (65%) for analysis. Participants without follow-up scans had similar baseline characteristics to those attending both scans, except lower mini-mental state examination scores (Table II in (Figure 2) , and sensitivity analyses ( Table 2 ). There was a significant interaction between baseline WMH volume and the intervention effect (AMD, −0.03; 95% CI, −0.06 to 0.00; P=0.03), implying that the intervention effect significantly increased with increasing baseline WMH volume (−0.03 mL/y per baseline mL of WMH). Analyses within quartiles of baseline WMH volume also suggested greater intervention effect in participants with higher baseline WMH volume (Table 2; Figure 3 ). New LI developed in 6 (9%) intervention and 2 (3%) control participants (odds ratio, 2.2; 95% CI, 0.4-12.1; P=0.36). Tables III and IV in the online-only Interaction: increase in the effect of the intervention per milliliter WMH at baseline, WMH load: WMH volume divided by total brain volume, model 1: adjusted for baseline WMH volume, model 2: additionally adjusted for total brain volume and change in total brain volume between scans 1 and 2, model 3: additionally adjusted for systolic and diastolic blood pressure, body mass index, smoking status, history of diabetes mellitus at baseline, serum cholesterol at baseline, history of cardiovascular disease at baseline, history of stroke or transient ischemic attack at baseline, and age at scan 1. CI indicates confidence interval; AMD, adjusted mean difference intervention vs control group; LI, lacunar infarct; NA, not applicable; and WMH, white matter hyperintensity. *P<0.05. Table V in the online-only Data Supplement lists relationship between potential risk factors and WMH progression. WMH volume at scan 1 was the strongest predictor of WMH increase (0.05 mL/ mL; 95% CI, 0.03-0.06; P<0.001). Baseline systolic BP, diastolic BP, mean arterial pressure, and BMI were significantly associated with WMH increase. WMH volume change was unaffected by changes in risk factors achieved during the study, with the potential exception of diastolic and mean arterial BP. Fitting quadratic curves and comparing regression coefficients within tertiles of continuous variables did not reveal any clear J-or U-shaped relationships with the possible exception of diastolic BP during the study (linear: R 2 =0.071, P=0.002, quadratic: R 2 =0.087, P=0.004). There was no excess mortality or difference in hospital admissions or serious adverse events for hypotension, syncope, electrolyte abnormalities, injurious falls, or acute kidney injury/failure between study arms.
Discussion
Intensive nurse-led vascular care in community-dwelling elderly with hypertension did not result in the prevention of WMH progression over a 3-year period, in spite of reducing BP and improving dyslipidemia. Secondary analyses suggest that the intervention was more effective in participants with higher baseline WMH volume. There was no effect on LI incidence, but numbers were low. WMH volume at scan 1 was the strongest predictor for WMH progression, followed by baseline BP and BMI.
The effects of combined treatment of multiple CVRFs on the progression of cerebrovascular lesions have not been studied widely. In the EVA trial (Evaluation of Vascular Care in Alzheimer's Disease), a multidomain cardiovascular intervention in Alzheimer disease patients with cerebrovascular lesions led to a 40% reduction of WMH progression.
14 In contrast to this study, the EVA trial intervention included antiplatelet therapy, which may have reduced WMH progression by preventing infarction. 4, 6 This corresponds to recent findings suggesting that WMH progression results from the accumulation of tiny infarcts, predominantly adjacent to existing WMH. 23 Our greater intervention effect in participants with higher baseline WMH volume is in line with findings of antihypertensive trials in cerebrovascular disease. 11, 24 Subgroup analyses in the overall preDIVA trial suggested stronger intervention effects on dementia prevention in participants with untreated hypertension at baseline. 15 These are likely participants with high WMH volume. In future studies, preventing cognitive decline through cardiovascular treatment may be more effective in persons with high WMH burden.
Other trials mainly evaluated the treatment of single CVRFs. One trial comparing candesartan to placebo, as add on to regular antihypertensive treatment in elderly with hypertension (systolic BP 160-179 mm Hg) reported a greater decrease in BP (systolic/diastolic, 6/3 mm Hg), accompanying ≈20% less WMH progression. 9 Another trial comparing perindopril+indapamide to placebo in individuals after stroke reported a greater decrease in BP (11.2/4.3 mm Hg) with 80% less WMH progression. 24 Our intervention also led to a greater reduction in BP (4.5/2.9 mm Hg) compared with the control condition but had no effect on WMH progression. This might be because of the differences in study population. However, we found no additional intervention benefit in subgroups with BP ≥160/100 mm Hg or a history of CVD/stroke/TIA. Another explanation may be that the reported effects are not caused by lower BP but specific to antihypertensive drug treatment. Previous observational and interventional studies on dementia suggest that specific antihypertensive classes and combinations may have intrinsic neuroprotective effects. [25] [26] [27] The proportion of participants initiating antihypertensive medication during our study was similar in both treatment arms (50% versus 49%). This might also explain why we found no effect on WMH progression in participants with untreated hypertension, whereas the preDIVA trial suggested a possible protective effect on dementia in this subgroup. Our substudy was not powered to assess such possible neuroprotective effects in sufficient detail. About hyperlipidemia, the greater proportion initiating statin therapy and greater decrease in cholesterol in intervention participants compared with controls did not result in an effect on WMH progression. Although confounding by indication may play a role, because more intervention participants had a history of CVD/stroke/TIA (both an indication for statin treatment and a risk factor for WMH progression), our findings correspond to other trials reporting no benefit of statins on WMH progression.
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Figure 3. Effect of the intervention in quartiles 1 (low) through 4 (high) of baseline white matter hyperintensity (WMH) volume. Depicted is the mean difference in WMH volume increase in mL/y for the intervention group compared with the control group adjusted for baseline WMH volume. Numbers on the x axis represent quartiles of WMH volume with 1 being the quartile with the lowest and 4 being the quartile with the highest WMH volume. The depicted effects within each quartile are not significant. The P value for interaction is for the interaction between baseline WMH volume in milliliter and the intervention effect, implying the effect of the intervention significantly improved with increasing baseline WMH volume (Table 2) .
A limitation of our study is the relatively small contrast in CVRF improvement between treatment arms. This may partly be caused by treatment initiated in control participants in response to the 2-year assessments, and the high standard of regular cardiovascular care in the Netherlands. Nonetheless, our 4.5/2.9 mm Hg BP difference between the groups is comparable to treatment effects in some large antihypertension randomized controlled trials, which reported clear clinical benefit. [28] [29] [30] The relatively healthy selection of preDIVA participants with hypertension in the MRI substudy may have reduced the intervention effect, especially because it seems greater in participants with high WMH burden. Furthermore, as the first MRI scan was conducted 2 to 3 years after initiating the preDIVA intervention, some effect may have already occurred before the first MRI was obtained, although treatment effects may not occur immediately. Finally, corresponding to recent insights, 31 our study may have been underpowered. Retrospectively, we had 80% power to detect ≈40% less WMH accumulation in the intervention group. From our data, assuming a linear relation, a decrease of 10 mm Hg in mean arterial BP would decrease the yearly WMH accumulation by about 0.11 mL, far less than the 0.28 mL/y needed to achieve a 40% difference. Other trials that did find treatment effects on WMH progression achieved ≈20 to 80% less increase. 9, 14, 24 Regarding LI, the 6% incidence over 3 years was less than the 12% to 19% expected based on other population-based studies. 16, 22 Because the number of participants with new LI was too low to allow adjustment in regression analyses, we did not perform extensive analyses on this outcome and our findings about LI are inconclusive.
In conclusion, despite positive effects on BP and dyslipidemia, multidomain nurse-led vascular care in communitydwelling older persons with hypertension did not decrease WMH accumulation over 3 years. Our results hint that the treatment of CVRFs may be effective in participants with high baseline WMH burden. The differences in CVRF improvement between intervention and control groups were modest, possibly because of the already high level of care in the Netherlands. Future trials evaluating the treatment of CVRFs to prevent WMH progression may be done in settings with lower levels of standard cardiovascular care or in participants with high WMH burden. Finally, future studies should shed light on the issue whether antihypertensive medication itself, or the resulting BP lowering, is beneficial in impeding WMH progression because this could affect treatment decisions.
